Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

Blood

Volumn 107, Issue 3, 2006, Pages 1227-1229

  Gillmore, Julian D ^a   Goodman, Hugh J ^a   Lachmann, Helen J ^a   Offer, Mark ^a   Wechalekar, Ashutosh D ^a   Joshi, Jayshree ^a   Pepys, Mark B ^a   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; KAPLAN MEIER METHOD; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 31544436321     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3253     Document Type: Article

References (19)

1. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999;17:262-267.
2. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med. 1998;91:141-157.
3. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257-262.
4. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290-298.
5. Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol. 1997;99:245-256.
6. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
7. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766-769.
8. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662-3670.
9. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 1999;24:853-855.
10. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000;26:963-969.
11. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
12. Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant. 1988;7:165-167.
13. McCarthy RE 3rd, Kasper EK. A review of the amyloidoses that infiltrate the heart. Clin Cardiol. 1998;21:547-552.
14. 123|-labeled serum amyloid P component. N Engl J Med. 1990;323:508-513.
15. Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci. 1994;87:289-295.
16. Rydh A, Suhr O, Hietala S-O, Åhlström KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709-713.
17. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
18. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142-1153.
19. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation. 1991;84:338-343.